Why Is Rocket Pharma Stock Up 15% Pre-Market Today?
admin | August 20, 2025 8:22 PM CST
The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.
Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.
The hold, imposed roughly three months ago, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.
Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.
Get updates to this developing story <directly on Stocktwits.<
READ NEXT
-
“The simple thing of everyday, which can become the secret of your health” – News Himachali News Himachali
-
Adani will get a check of 2,400 crores from foreign banks, know what is complete planning
-
Vishwakarma Jayanti 2025: The importance of worshiping tools and worshiping Lord Vishwakarma at the workplace
-
EPFO records highest ever net addition of nearly 22 lakh members in June
-
JPMorgan, Japan’s MUFG Near $22 Billion Financing Deal For Data Center In Texas: Report
